



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1645

p#11

Applicants: Christopher William Ogden, James Adshead, Anna Maria Kessling,
and Bijan Khoubehi

Serial No.: 09/933,548

Art Unit: 1645

Filed: August 20, 2001

Examiner: Not Yet Assigned

For: *DIAGNOSIS AND TREATMENT OF PROSTATE CANCER*

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

SEP 24 2002

INFORMATION DISCLOSURE STATEMENT

TECH CENTER 1600/2900

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including seven (7) pages of Form PTO-1449 and copies of fifty (50) documents cited therein. We were unable to locate copies of those references indicated with an asterisk (*). We will forward copies of these shortly.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
4,376,110	03-08-1983	David et al.	436/513
4,486,530	12-04-1984	David et al.	435/7
5,747,250	05-05-1998	Gruss et al.	1/68
6,071,697	06-06-2000	Sosa-Pineida et al.	435/6

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
0 655 926 B1	06-07-1995	Max-Planck-Gesellschaft	EP
WO 94/03196 A1	02-17-1994	Max Planck-Gesellschaft	PCT
WO 97/15686 A1	05-01-1997	Imperial Cancer Research Technology Limited	PCT
WO 96/02674 A1	02-01-1996	The Johns Hopkins University School of Medicine	PCT
WO 95/32214 A1	11-30-1995	Canji, Inc.	PCT

Publications

ADAMS, et al., "Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testes," *Genes & Development* 6:1589-1607 (1992).

BALAGUER, et al., "Quantification of DNA sequences obtained by polymerase chain reaction using a bioluminescent adsorbent," *Analytical Biochemistry* 195:105-110 (1991).

BERNASCONI, et al., "Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins," *Proc Natl Acad Sci USA* 93:13164-69 (1996).

BISCHOFF, et al., "An adventure mutant that replicates selectively in p53-deficient human tumor cells," *Science* 274:373-376 (1996).

BRAWER, "Prostate Specific Antigen," *Acta Oncol.* 30:161-168 (1991).

BROTHMAN, et al., "Frequency and pattern of karyotypic abnormalities in human prostate cancer," *Cancer Research* 50:3795-3803 (1990).

*BUSSLINGER, et al., "The role of BSAP (Pax-5) in B-cell development," *Current Opinion in Genetics and Development* 5: 595-601 (1995).

Cancer Statistics: Registrations Engalnd and Wales OPCS MBI No. 22, Her Majesty's Stationery Office (1994).

CANNON-ALBRIGHT & EELES, "Progress in prostate cancer," *Nature Genetics* 9:336-338 (1995).

CHAMBERLAIN, et al., "Report prepared for the health technology assessment panel of the NHS execution on the diagnosis, management, treatment and costs of prostate cancer in England and Wales," *British Journal of Urology* 79(Suppl. 3):1-32 (1997).

CHAN, et al., "Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study," *Science* 279:563-566 (1998).

COMPTON, Nucleic acid sequence-based amplification," *Nature* 350:91-92 (1991).

COTTEN, et al., "High-efficiency receptor-mediated delivery of small and large (48 kilobase) gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles," *Proc Natl Acad Sci USA* 89:6094-6098 (1992).

CULVER, et al., "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors," *Science* 256:1550-1552 (1992).

CURIEL, "Adenovirus facilitation of molecular conjugate-mediated gene transfer," *Prog Med Virol* 40:1-18 (1993).

DICESARE, et al., "A high-sensitivity electrochemiluminescence-based detection system for automated PCR product quantitation," *BioTechniques* 15:152-157 (1993).

DRESSLER, et al., "Deregulation of *Pax-2* expression in transgenic mice generates severe kidney abnormalities," *Nature* 362:665-67 (1993).

*DRESSLER, et al., "Pax2, a new murine paired-box-containing gene and its expression in the developing excretory system," *Development* 109(4): 787-795 (1990).

Future Oncology "Prostate Cancer-Part II: Diagnosis, Staging, Prognosis, Screening, and Novel Molecular Markers," 3(12): 1998.

*GANN, et al., "A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer," *JAMA* 273: 289-294 (1995).

GAO, et al., "Diagnostic and prognostic markers for human prostate cancer," *The Prostate* 31:264-281 (1997).

GAO, et al., "High frequency of mutator phenotype in human prostatic adenocarcinoma," *Oncogene* 9:2999-3003 (1994).

GLEASON, "Classification of prostatic carcinomas," *Cancer Chemother Rep.* 50:125-128 (1966).

GNARRA & DRESSLER, "Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides," *Cancer Research* 55(18):4092-8 (1995).

JACOBS, et al., "Thermal stability of oligonucleotide duplexes is sequence independent in tetraalkylammonium application to identifying recombinant DNA clones," *Nucl. Acids Res.* 16:4367 (1988).

KHOUBEHI, et al., "The expression of the PAX2 in human prostate cancer," *Am J Human Genetics* 65(Suppl. 4):A132 (1999).

KHOUBEHI, et al., "Expression of the developmental and oncogenic PAX2 gene in human prostate cancer," *J Urology* 165(6.1): 2115-2120.

KOONTZ, et al., "Mitomycin for patients who have failed on thiotepa," *Urology* 26(4 Suppl.):30-31 (1985).

KURIYAMA, et al., "A Potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector," *Cell Structure and Function* 16:503-510 (1991).

LEDLEY, "Nonviral gene therapy: The promise of genes as pharmaceutical products," *Human Gene Therapy* 6:1129-1144 (1995).

LI, et al., "PTEN, a putative Protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer," *Science* 275:1943-1947 (1997).

*LUNDWALL, "Characterization of the gene for prostate-specific antigen, a human glandular kallikrein," *Biochem. Biophys. Res. Comm.* 161(3): 1151-1159 (1989).

MARTIN & PAPAHAJIOPOULOS, et al., "Irreversible coupling of immunoglobulin fragments to preformed vesicles," *J Biol Chem* 257:286-88 (1982).

*MASSENKEIL, et al., "P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer," *Anticancer Res.* 14(6B): 2785-2790 (1994).

*MAULBECKER & GRUSS, "The oncogenic potential of Pax genes," *EMBO Journal* 12(6): 2361-2367 (1993).

MICHAEL, et al., "Addition of a short peptide ligand to the adenovirus fiber protein," *Gene Therapy* 2:660-668 (1982).

*MILLER & VILE, "Targeted vectors for gene therapy," *FASEB Journal* 9(2): 190-199 (1995).

Mortality Statistics: Cause. England and Wales. OPCS DH2 19, Her Majesty's Stationery Office, 1993.

NÄSSANDER, et al., "In vivo targeting of OV-TL 3 immunoliposomes to Ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice," *Cancer Research* 52:646-653 (1992).

*NIHEI, et al., "Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10," *Genes, Chromosomes & Cancer* 14(2): 112-119 (1995).

*PHELPS & DRESSLER, "Aberrant expression of Pax-2 in Danforth's short tail (Sd) mice," *Developmental Biology* 157(1): 251-258 (1993).

*POGREBNIAK, et al., "Targetted phototherapy with sensitizer-monoclonal antibody conjugate and light," *Surgical Oncology* 2(1): 31-42, 1993.

*RIEGMAN, et al., "Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene," *Biochem Biophys. Res. Comm.* 159(1): 95-102 (1989).

RYAN, et al., "Repression of Pax-2 by WT1 during normal kidney development," *Development* 121: 867-875 (1995).

SAIKI, et al., "Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase," *Science* 239:487-491 (1988).

*SANYANUSIN, et al., "Fenomic structure of the human PAX2 gene," *Genomics* 35(1): 258-261 (1996).

SCHÄFER, et al., "Molecular cloning and characterization of a human PAX-7 cDNA expressed in normal and neoplastic myocytes," *Nuc. Acids Res.* 22(22): 4574-4582 (1994).

*SMITH & CATALONA, "Interexaminer variability of digital rectal examination in detecting prostate cancer," *Urology* 45(1): 70-74 (1995).

STECK, et al., "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers," *Nature Genetics* 15: 356-363 (1997).

*STUART & GRUSS, "PAX genes: What's new in developmental biology and cancer?" *Human Mol. Gen.* 4: 1717-1720 (1995).

*STUART, et al., "Loss of p53 function through PAX-mediated transcriptional repression," *EMBO Journal* 14: 5638-5645 (1995).

STUART, et al., "Mammalian PAX genes," *Annu Rev. Genet.* 27: 219-236 (1993).

STUART, et al., "PAX and HOX in Neoplasia," *Adv. Genet.* 33: 255-274 (1995).

WAGNER, et al., "Transferrin-polycation conjugates as carriers for DNA uptake into cells," *Proc. Nat. Acad. Sci. USA* 87: 3410-3414 (1990).

*WALKER, et al., "Strand displacement amplification – an isothermal, in vitro DNA amplification technique," *Nuc. Acids. Res.* 20(7): 1691-1696 (1992).

YARMUSH, et al., "Antibody targeted photolysis," *Crit. Rev. Therap. Drug Carrier Syst.* 10(3): 197-252 (1993).


U.S.S.N.: 09/933,548
Filed: August 20, 2001
INFORMATION DISCLOSURE STATEMENT

ZENKLUSEN, et al., "Loss of heterozygosity in human primary prostate carcinomas: A possible tumor suppressor gene at 7q31.1," *Cancer Res.* 54: 6370-6373 (1994).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: September 20, 2002


HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com

U.S.S.N.: 09/933,548
Filed: August 20, 2001
INFORMATION DISCLOSURE STATEMENT

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: September 20, 2000


Erica C. Boughner

ATL1 #519202 v1

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known		RECEIVED SEP 24 2002 TECH CENTER 1600/2900
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/933,548	
		Filing Date	August 20, 2001	
		First Named Inventor	Christopher William Ogden	
		Group Art Unit	1645	
		Examiner Name		
Sheets of 7	Attorney Docket Number	NORT 100		

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ADAMS, et al., "Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testes," <i>Genes & Development</i> 6:1589-1607 (1992).	
		BALAGUER, et al., "Quantification of DNA sequences obtained by polymerase chain reaction using a bioluminescent adsorbent," <i>Analytical Biochemistry</i> 195:105-110 (1991).	
		BERNASCONI, et al., "Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins," <i>Proc Natl Acad Sci USA</i> 93:13164-69 (1996).	
		BISCHOFF, et al., "An adventure mutant that replicates selectively in p53-deficient human tumor cells," <i>Science</i> 274:373-376 (1996).	
		BRAWER, "Prostate Specific Antigen," <i>Acta Oncol.</i> 30:161-168 (1991).	
		BROTHMAN, et al., "Frequency and pattern of karyotypic abnormalities in human prostate cancer," <i>Cancer Research</i> 50:3795-3803 (1990).	
		BUSSLINGER, et al., "The role of BSAP (Pax-5) in B-cell development," <i>Current Opinion in Genetics and Development</i> 5:595-601 (1995).	
		Cancer Statistics: Registrations England and Wales OPCS MBI No. 22, Her Majesty's Stationery Office (1994).	
		CANNON-ALBRIGHT & EELES, "Progress in prostate cancer," <i>Nature Genetics</i> 9:336-338 (1995).	
		CHAMBERLAIN, et al., "Report prepared for the health technology assessment panel of the NHS execution on the diagnosis, management, treatment and costs of prostate cancer in England and Wales," <i>British Journal of Urology</i> 79(Suppl. 3):1-32 (1997).	
		CHAN, et al., "Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study," <i>Science</i> 279:563-566 (1998).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Complete if Known

RECEIVED

SEP 24 2002

TECH CENTER 1600/2900

Application Number	09/933,548
Filing Date	August 20, 2001
First Named Inventor	Christopher William Ogden
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	NORT 100

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		COMPTON, Nucleic acid sequence-based amplification," <i>Nature</i> 350:91-92 (1991).	
		COTTEN, et al., "High-efficiency receptor-mediated delivery of small and large (48 kilobase) gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles," <i>Proc Natl Acad Sci USA</i> 89:6094-6098 (1992).	
		CULVER, et al., "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors," <i>Science</i> 256:1550-1552 (1992).	
		CURIEL, "Adenovirus facilitation of molecular conjugate-mediated gene transfer," <i>Prog Med Virol</i> 40:1-18 (1993).	
		DICESARE, et al., "A high-sensitivity electrochemiluminescence-based detection system for automated PCR product quantitation," <i>BioTechniques</i> 15:152-157 (1993).	
		DRESSLER, et al., "Deregulation of <i>Pax-2</i> expression in transgenic mice generates severe kidney abnormalities," <i>Nature</i> 362:665-67 (1993).	
		DRESSLER, et al., "Pax2, a new murine paired-box-containing gene and its expression in the developing excretory system," <i>Development</i> 109(4): 787-795 (1990).	
		<u>Future Oncology</u> "Prostate Cancer-Part II: Diagnosis, Staging, Prognosis, Screening, and Novel Molecular Markers," 3(12): 1998.	
		GANN, et al., "A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer," <i>JAMA</i> 273: 289-294 (1995).	
		GAO, et al., "Diagnostic and prognostic markers for human prostate cancer," <i>The Prostate</i> 31:264-281 (1997).	
		GAO, et al., "High frequency of mutator phenotype in human prostatic adenocarcinoma," <i>Oncogene</i> 9:2999-3003 (1994).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/933,548
		Filing Date	August 20, 2001
		First Named Inventor	Christopher William Ogden
		Group Art Unit	1645
		Examiner Name	
		Attorney Docket Number	NORT 100

RECEIVED

SEP 24 2002

TECH CENTER 1600/2900



OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		GLEASON, "Classification of prostatic carcinomas," <i>Cancer Chemother Rep.</i> 50:125-128 (1966).	
		GNARRA & DRESSLER, "Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides," <i>Cancer Research</i> 55(18):4092-8 (1995).	
		JACOBS, et al., "Thermal stability of oligonucleotide duplexes is sequence independent in tetraalkylammonium application to identifying recombinant DNA clones," <i>Nucl. Acids Res.</i> 16:4367 (1988).	
		KHOUBEHI, et al., "The expression of the PAX2 in human prostate cancer," <i>Am J Human Genetics</i> 65(Suppl. 4):A132 (1999).	
		KHOUBEHI, et al., "Expression of the developmental and oncogenic PAX2 gene in human prostate cancer," <i>J Urology</i> 165(6.1): 2115-2120.	
		KOONTZ, et al., "Mitomycin for patients who have failed on thiotepa," <i>Urology</i> 26(4 Suppl.):30-31 (1985).	
		KURIYAMA, et al., "A Potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector," <i>Cell Structure and Function</i> 16:503-510 (1991).	
		LEDLEY, "Nonviral gene therapy: The promise of genes as pharmaceutical products," <i>Human Gene Therapy</i> 6:1129-1144 (1995).	
		LI, et al., "PTEN, a putative Protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer," <i>Science</i> 275:1943-1947 (1997).	
		LUNDWALL, "Characterization of the gene for prostate-specific antigen, a human glandular kallikrein," <i>Biochem. Biophys. Res. Comm.</i> 161(3): 1151-1159 (1989).	
		MARTIN & PAPAHAJOPOULOS, et al., "Irreversible coupling of immunoglobulin fragments to preformed vesicles," <i>J Biol Chem</i> 257:286-88 (1982).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+


Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 		Application Number	09/933,548
		Filing Date	August 20, 2001
		First Named Inventor	Christopher William Ogden
		Group Art Unit	1645
		Examiner Name	
		Attorney Docket Number	NORT 100
Sheet 5	of 7		

RECEIVED

SEP 24 2002

TECH CENTER 1600/2900

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		MASSENKEIL, et al., "P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer," <i>Anticancer Res.</i> 14(6B): 2785-2790 (1994).	
		MAULBECKER & GRUSS, "The oncogenic potential of Pax genes," <i>EMBO Journal</i> 12(6): 2361-2367 (1993).	
		MICHAEL, et al., "Addition of a short peptide ligand to the adenovirus fiber protein," <i>Gene Therapy</i> 2:660-668 (1982).	
		MILLER & VILE, "Targeted vectors for gene therapy," <i>FASEB Journal</i> 9(2): 190-199 (1995).	
		Mortality Statistics: Cause. England and Wales. OPCS DH2 19, Her Majesty's Stationery Office, 1993.	
		NASSANDER, et al., "In vivo targeting of OV-TL 3 immunoliposomes to Ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice," <i>Cancer Research</i> 52:646-653 (1992).	
		NIHEI, et al., "Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10," <i>Genes, Chromosomes & Cancer</i> 14(2): 112-119 (1995).	
		PHELPS & DRESSLER, "Aberrant expression of Pax-2 in Danforth's short tail (Sd) mice," <i>Developmental Biology</i> 157(1): 251-258 (1993).	
		POGREBNIK, et al., "Targeted phototherapy with sensitizer-monoclonal antibody conjugate and light," <i>Surgical Oncology</i> 2(1): 31-42, 1993.	
		RIEGMAN, et al., "Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene," <i>Biochem Biophys. Res. Comm.</i> 159(1): 95-102 (1989).	
		RYAN, et al., "Repression of Pax-2 by WT1 during normal kidney development," <i>Development</i> 121: 867-875 (1995).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

RECEIVED

Substitute for form 1449A/PTO		Complete if Known	
<p>Use as many sheets as necessary)</p>		Application Number	09/933,548
		Filing Date	August 20, 2001
		First Named Inventor	Christopher William Ogden
		Group Art Unit	1645
		Examiner Name	
Sheet 6 of 7	Attorney Docket Number	NORT 100	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		SAIKI, et al., "Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase," <i>Science</i> 239:487-491 (1988).	
		SANYANUSIN, et al., "Fenomic structure of the human PAX2 gene," <i>Genomics</i> 35(1): 258-261 (1996).	
		SCHÄFER, et al., "Molecular cloning and characterization of a human PAX-7 cDNA expressed in normal and neoplastic myocytes," <i>Nuc. Acids Res.</i> 22(22): 4574-4582 (1994).	
		SMITH & CATALONA, "Interexaminer variability of digital rectal examination in detecting prostate cancer," <i>Urology</i> 45(1): 70-74 (1995).	
		STECK, et al., "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers," <i>Nature Genetics</i> 15: 356-363 (1997).	
		STUART & GRUSS, "PAX genes: What's new in developmental biology and cancer?" <i>Human Mol. Gen.</i> 4: 1717-1720 (1995).	
		STUART, et al., "Loss of p53 function through PAX-mediated transcriptional repression," <i>EMBO Journal</i> 14: 5638-5645 (1995).	
		STUART, et al., "Mammalian PAX genes," <i>Annu Rev. Genet.</i> 27: 219-236 (1993).	
		STUART, et al., "PAX and HOX in Neoplasia," <i>Adv. Genet.</i> 33: 255-274 (1995).	
		WAGNER, et al., "Transferrin-polycation conjugates as carriers for DNA uptake into cells," <i>Proc. Nat. Acad. Sci. USA</i> 87: 3410-3414 (1990).	
		WALKER, et al., "Strand displacement amplification -- an isothermal, in vitro DNA amplification technique," <i>Nuc. Acids. Res.</i> 20(7): 1691-1696 (1992).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+


Please type a plus sign (+) inside this box →



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/933,548
		Filing Date	August 20, 2001
		First Named Inventor	Christopher William Ogden
		Group Art Unit	1645
		Examiner Name	
Sheets 7 of 7	Attorney Docket Number	NORT 100	



OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		YARMUSH, et al., "Antibody targeted photolysis," <i>Crit. Rev. Therap. Drug Carrier Syst.</i> 10(3): 197-252 (1993).	
		ZENKLUSEN, et al., "Loss of heterozygosity in human primary prostate carcinomas: A possible tumor suppressor gene at 7q31.1," <i>Cancer Res.</i> 54: 6370-6373 (1994).	

RECEIVED

SEP 24 2002

TECH CENTER 1600/2900

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Check Requested	N/A
-----------------	-----

ATL1 #544035 v1